Gaëlle JamarNov 29, 20221 minIntellia’s Modular CRISPR/Cas9 Gene Editing Platform for the Treatment of DiseaseLaura Sepp-Lorenzino, Ph.D., Executive Vice President, Chief Scientific Officer, Intellia Therapeutics Laura Sepp-Lorenzino, Ph.D....
Gaëlle JamarNov 29, 20221 minSafety considerations in therapeutic genome editingToni Cathomen, University of Freiburg Toni Cathomen is Director of the Institute for Transfusion Medicine and Gene Therapy at the Medical...
Gaëlle JamarNov 29, 20221 minRepurposing of bacterial CRISPR-Cas immunity for genome editingVirgis Siksnys, Vilnius University, Institute of Biotechnology Video available to ESGCT members only Virginijus Siksnys studied chemistry...